Live price temporarily unavailable.
Unicycive Therapeutics (UNCY) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | $951.0K | $675.0K | — | — |
| Growth (year over year) | — | — | — | −29.0% | — | — |
| Operating income | −$2.02M | −$8.98M | −$18.1M | −$20.8M | −$32.1M | −$29.5M |
| Operating margin | — | — | −1898.2% | −3077.6% | — | — |
| Net income | −$2.26M | −$10.0M | −$18.1M | −$30.5M | −$36.7M | −$26.6M |
| Net margin | — | — | −1898.8% | −4525.0% | — | — |
| EPS (diluted) | — | −$8.60 | −$12.00 | −$12.80 | −$5.65 | −$1.67 |
| Balance sheet | ||||||
| Cash and equivalents | — | $16.6M | $455.0K | $9.70M | $26.1M | $29.2M |
| Total assets | $204.0K | $18.7M | $2.82M | $14.2M | $31.7M | $49.1M |
| Total liabilities | $2.88M | $2.26M | $3.28M | $18.0M | $24.2M | $18.9M |
| Shareholders' equity | −$2.67M | $16.5M | −$466.0K | −$3.81M | $7.43M | $30.2M |
| Cash flow | ||||||
| Operating cash flow | −$1.46M | −$5.77M | −$15.7M | −$18.3M | −$28.6M | −$31.3M |
| Capital expenditure | — | $29.0K | $2.00K | $12.0K | $72.0K | $24.0K |
| Free cash flow | — | −$5.80M | −$15.7M | −$18.3M | −$28.6M | −$31.3M |
| Dividends paid | — | — | — | $900.0K | $1.09M | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$6.25M | −$9.26M | −$7.99M | −$6.96M | −$7.34M | −$7.22M | −$8.44M | −$10.1M |
| Net income | −$4.10M | −$21.5M | $570.0K | −$6.45M | −$6.01M | −$14.7M | −$12.8M | −$1.72M |
| EPS (diluted) | −$0.46 | $2.41 | −$0.50 | −$0.52 | −$0.33 | −$0.32 | −$0.54 | −$0.06 |
| Balance sheet | ||||||||
| Cash and equivalents | $32.3M | $26.1M | $19.8M | $22.3M | $42.7M | $29.2M | $37.4M | $44.2M |
| Total assets | $38.6M | $31.7M | $27.9M | $30.0M | $50.6M | $49.1M | $64.4M | $72.0M |
| Total liabilities | $10.7M | $24.2M | $16.7M | $13.6M | $13.1M | $18.9M | $26.7M | $18.8M |
| Shareholders' equity | −$27.9M | $7.43M | $11.3M | $16.4M | $37.5M | $30.2M | $37.7M | $53.3M |
| Cash flow | ||||||||
| Operating cash flow | −$9.25M | −$6.55M | −$8.90M | −$8.42M | −$5.96M | −$8.03M | −$6.24M | −$7.60M |
| Capital expenditure | $24.0K | $22.0K | $16.0K | $6.00K | $2.00K | $0 | $8.00K | −$1.00K |
| Free cash flow | −$9.28M | −$6.57M | −$8.92M | −$8.43M | −$5.96M | −$8.03M | −$6.25M | −$7.60M |
| Dividends paid | $0 | $0 | — | — | — | — | — | — |
From Unicycive Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Unicycive Therapeutics in our feed yet.